Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0293162 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Tinei Shamu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Newlands Clinic, Harare, Zimbabwe. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, Piperazines, Pyridones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FIC NIH HHS, NIAID NIH HHS, Fogarty International Center.
Abstract (Originalsprache)
There are few data from sub-Saharan Africa on the virological outcomes associated with second-line ART based on protease inhibitors or dolutegravir (DTG). We compared viral load (VL) suppression among people living with HIV (PLWH) on atazanavir (ATV/r)- or DTG-based second-line ART with PLWH on efavirenz (EFV)-based first-line ART. We analyzed data from the electronic medical records system of Newlands Clinic in Harare, Zimbabwe. We included individuals aged ≥12 years when commencing first-line EFV-based ART or switching to second-line DTG- or ATV/r-based ART with ≥24 weeks follow-up after start or switch. We computed suppression rates (HIV VL
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Newlands Clinic, Harare, Zimbabwe.
- Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
- Graduate School of Health Sciences, University of Bern, Bern, Switzerland.
- Centre for Infectious Disease Epidemiology and Research, School of Public Health, University of Cape Town, Cape Town, South Africa.
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
- Department of Pharmacy and Pharmaceutical Sciences, University of Zimbabwe, Harare, Zimbabwe.
ORCID-Profile: Tinei Shamu, Nanina Anderegg
Förderung
- FIC NIH HHS
- NIAID NIH HHS
- Fogarty International Center
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Shamu, T., Egger, M., Mudzviti, T., Chimbetete, C., Manasa, J., & Anderegg, N. (2024). Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study. PLOS ONE. https://doi.org/10.1371/journal.pone.0293162
Vancouver
Shamu T, Egger M, Mudzviti T, Chimbetete C, Manasa J, Anderegg N. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study. PLOS ONE. 2024. doi:10.1371/journal.pone.0293162
BibTeX
@article{Shamu2024,
author = {Shamu, Tinei and Egger, Matthias and Mudzviti, Tinashe and Chimbetete, Cleophas and Manasa, Justen and Anderegg, Nanina},
title = {Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0293162}
}
EUVIMED